Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;41(4):461-464.
doi: 10.1007/s10585-023-10263-1. Epub 2024 Jan 28.

Neoadjuvant therapy for resectable melanoma

Cimarron E Sharon  1 , Giorgos C Karakousis  2
Affiliations
Review

Neoadjuvant therapy for resectable melanoma

Cimarron E Sharon et al. Clin Exp Metastasis. 2024 Aug.

Abstract

The standard of care for patients with resectable stage III/IV melanoma classically included upfront resection with adjuvant therapy. However, in more recent years, the amount of systemic therapies available for neoadjuvant use for these patients has increased. This article reviewed clinical trials investigating neoadjuvant therapy for patients with resectable stage III/IV melanoma. The outcomes of these trials have identified optimal treatment regimens to maximise patient response and minimize toxicities. Additionally, the date demonstrate advantages to neoadjuvant treatment compared to adjuvant therapy alone. Further research is needed to utilize a patient's response to neoadjuvant treatment for prognostication and creation of an individualized treatment plan.

Keywords: Immune therapy; Melanoma; Neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations

Competing interests The authors declare no competing interests.

References

    1. Witt RG, Erstad DJ, Wargo JA (2022) Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Ther Adv Med Oncol 14:17588359221083052. 10.1177/17588359221083052 - DOI - PMC - PubMed
    1. Huang AC, Orlowski RJ, Xu X et al. (2019) A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 03(3):454–461. 10.1038/s41591-019-0357-y - DOI - PMC - PubMed
    1. Amaria RN, Reddy SM, Tawbi HA et al. (2018) Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 11(11):1649–1654. 10.1038/s41591-018-0197-1 - DOI - PMC - PubMed
    1. Blank CU, Rozeman EA, Fanchi LF et al. (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 11(11):1655–1661. 10.1038/s41591-018-0198-0 - DOI - PubMed
    1. Rozeman EA, Menzies AM, van Akkooi ACJ et al. (2019) Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 07(7):948–960. 10.1016/S1470-2045(19)30151-2 - DOI - PubMed

MeSH terms

LinkOut - more resources